Androgen receptor pathway activity assay for sepsis diagnosis and prediction of favorable prognosis

Wilbert Bouwman¹, Wim Verhaegh¹, Anja van de Stolpe²

¹Philips Research, Eindhoven, Netherlands, ²Philips Molecular Pathway Dx, Eindhoven,

Netherlands

Supplementary information (I)



Figure S1: PAS for pathways NF κ B, Notch, ER, FOXO, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE26440 [1]. Pathway activity score on Y-axis in log2 odds. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S2: PAS for pathways NFκB, NOTCH, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE26378 [1]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S3: PAS for pathways NFκKB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE4607 [2]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S4: PAS for pathways NFκB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE13904 [3]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S5: PAS for pathways NFκB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE8121 [4]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S6: PAS for pathways NFκB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE9692 [5]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S7: PAS for pathways NFκB, Notch, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE57065 [6]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p<0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S8: PAS for pathways NFκB, Notch, , ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 of dataset GSE95233 [7]. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p <0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 or ns (not significant).



Figure S9: ROC curves for diagnosis of sepsis for pathways NFκB, Notch, TGFB, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2. Controls and sepsis patients (sepsis and sepsis shock) from dataset GSE26440 [1], GSE26378 [1], GSE4607 [2], GSE13904 [3], GSE8121[4] and GSE9692 [5] are included.



Figure S10: ROC curves for survival of sepsis for pathways NκKB, Notch, TGF6, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2 sepsis survival and non survival patients from dataset GSE26440 [1], GSE26378 [1], GSE4607 [2], and GSE9692 [5] are included.



Figure S11: PAS of day 1 versus day 3 of sepsis survival and non-survival patients for pathways NFκB, Notch, TGFB, ER, FOXO-PI3K, HH, MAPK-AP1, JAK-STAT3 and JAK-STAT1/2. Dataset GSE95233 [7].



Figure S12: AR pathway activity analysis of dataset GSE161731 [8] of whole blood samples from patients presenting to the emergency department with acute respiratory infection caused by influenza (virus), or bacterial pneumonia and matched healthy controls. RNAseq data were analyzed with our signal transduction pathway assays converted to RNAseq as input data. *Two sided Mann–Whitney–Wilcoxon statistical tests is performed; p-values are indicated in the figures.*

		Sample		GSM numbers of	
Dataset	Sample type	prep	Population information	removed duplicates	Pubmed
GSE26440	blood samples were obtained within 24	Whole	Children =10 years of age	GSM648594	https://pubmed.ncl
	septic shock	PaxGene™	care unit (PICU) and meeting	GSM648650	
		Blood RNA	pediatric-specific criteria for septic	GSM648652	
		System	shock were eligible for enrollment	GSM648653	
				GSM648657	
				GSM648675	
				GSM648680	
				GSM648719	
GSE26378	blood samples were obtained within 24 hours of initial presentation to the PICU with septic shock	Whole blood and PaxGene™ Blood RNA System	Children =10 years of age admitted to the pediatric intensive care unit (PICU) and meeting pediatric-specific criteria for septic shock were eligible for enrollment	GSM647621	https://pubmed.ncbi.
GSE4607	Blood samples were obtained within 24 hours of admission to the PICU, heretofore referred to as "Day 1" of septic shock.	Whole blood and PaxGene™ Blood RNA System	Children < 10 years of age admitted to the pediatric intensive care unit (PICU) and meeting criteria for septic shock were eligible for the study. Septic shock was defined using pediatric- specific criteria		https://pubmed.ncl
GSE13904	blood samples were obtained on day 1 of the study and when possible on day 3 of the study. Day 1 of the study was defined as within the first 24 hours of meeting criteria for a given study category in any PICU patient, whether at admission to the PICU or after initial admission to the PICU with a nonstudy-related classification. Day 3 of the study was defined as 48 hours after drawing day 1 samples, regardless of the PICU status.	Whole blood and PaxGene™ Blood RNA System	Children ≤10 years of age admitted to the pediatric intensive care units (PICUs) and meeting published, pediatric-specific criteria for SIRS, sepsis, or septic shock were eligible	GSM350141 GSM350142 GSM350144 GSM350145 GSM350146 GSM350147 GSM350154 GSM350209 GSM350238 GSM350238 GSM350246 GSM350246 GSM350249 GSM350257 GSM350267 GSM350267 GSM350271 GSM350271 GSM350272 GSM350273 GSM350274 GSM350275 GSM350279	https://pubmed.ncl

				GSM350286	
				GSM350291	
				GSM350293	
				GSM350294	
				GSM350297	
				GSM350298	
				GSM350299	
				GSM350300	
				GSM350302	
				GSM350303	
				GSM350304	
				GSM350309	
				GSM350310	
				GSM350316	
				GSM350317	
				GSM350325	
				GSM350326	
				GSM350343	
				GSM350344	
				GSM350347	
				GSM350348	
				GSM350350	
				GSM350351	
				GSM350358	
				GSM350363	
GSE8121	Blood samples for RNA isolation were	Whole	Children < ten years of age	GSM201231	https://pubmed.ncl
	obtained within 24 h of admission to the	blood and PayGene™	admitted to the PICU and meeting	GSM201241	
	shock. An additional sample was obtained	Blood RNA	eligible for the study	GSM201242	
	for RNA isolation 48 hours after obtaining	System		GSM201245	
	the day one sample ("day three" of septic			GSM201246	
	SHOCK).			GSM201251	
				GSM201252	
				GSM201254	
				GSM201256	
				GSM201259	
				GSM201261	
				GSM201262	
				GSM201263	
				GSM201265	
				GSM201268	
				GSM201270	
				GSM201270	
				GSM201272	
				GSM2012213	
				GSM201202	
			l	02101201282	

				GSM201283	
				GSM201286	
				GSM201291	
				GSM201292	
				GSM201295	
				GSM201297	
				GSM201299	
				GSM201201	
GSE9692	blood samples for RNA isolation were	Whole	Children < 10 years of age	GSM201301	https://pubmed.nc
	obtained within 24 hours of admission to	blood and	admitted to the pediatric intensive	GSIM244479	
	the PICU, heretofore referred to as "day 1"	PaxGene™	care unit (PICU), and meeting	GSIM244483	
	of septic shock.	Blood RNA	pediatric-specific criteria for septic	GSIM244484	
		System	snock were eligible for the study	GSM244486	
				GSM244490	
				GSM244491	
				GSM244492	
				GSM244497	
				GSM244504	
				GSM244507	
GSE57065	Blood samples were collected within 30 min	Whole	18 years and above were enrolled		https://pubmed.nc
	and 24 and 48 h after shock.	blood and	at the onset of septic shock.		
		PaxGene™ Blood BNA			
		System			
GSE95233	Septic shock patients were sampled twice,	Whole	Septic shock patients (adults)		https://pubmed.nc
	at admission, and a second time at D2 or D3.	blood and	admitted to the Intensive Care		
		PaxGene™	Unit (ICU) were compared to		
		Blood RNA	healthy volunteers, and according		
		System	to day 28 survival status.		
GSE161731	whole blood samples from patients	Whole	Patients presenting to the		https://pubmed.nc
	presenting to the emergency department	blood and	emergency department with acute		
	with acute respiratory infection caused by	PaxGene™	respiratory infections		
	influenza (virus), or bacterial pneumonia	BIOOD RNA			
	and matched healthy controls	System			

Supplementary Table 1: Public clinical datasets from the GEO database used in used in study.

r							
	Healthy controls Children (log2 odds scores)						
Pathway	Mean	SD	Mean + 1 SD	Mean + 2 SD			
MAPK-AP1	-9.67	1.73	-7.94	-6.20			
AR	-15.37	1.52	-13.85	-12.33			
ER	-18.22	1.10	-17.12	-16.02			
HH*	-13.86	1.45	-15.31	-16.76			
ΝϜκΒ	1.49	3.01	4.50	7.51			
Notch	-5.61	1.78	-3.84	-2.06			
FOXO-PI3K	5.12	3.33	8.45	11.77			
JAK-STAT1/2	-5.54	2.34	-3.20	-0.86			
JAK-STAT3	-7.86	2.00	-5.86	-3.85			
TGFβ	-17.05	1.63	-15.42	-13.79			

	Healthy controls Adults (log2 odds scores)						
Pathway	Mean	SD	Mean + 1 SD	Mean + 2 SD			
MAPK-AP1	-8.04	0.94	-7.10	-6.16			
AR	-12.44	1.44	-11.01	-9.57			
ER	-15.53	1.88	-13.65	-11.77			
HH*	-12.51	1.73	-10.78	-9.04			
ΝϜκΒ	4.29	3.50	7.79	11.29			
Notch	-4.74	1.62	-3.12	-1.50			
FOXO-PI3K	8.49	3.22	11.70	14.92			
JAK-STAT1/2	-5.59	3.12	-2.47	0.65			
JAK-STAT3	-1.61	1.54	-0.07	1.47			
TGFβ	-13.01	1.83	-11.18	-9.35			

	Healthy controls Children + Adults (log2 odds scores)					
Pathway	Mean	SD	Mean + 1 SD	Mean + 2 SD		
MAPK-AP1	-9.21	1.71	-7.49	-5.78		
AR	-14.54	2.00	-12.54	-10.54		
ER	-17.46	1.83	-15.63	-13.80		
HH*	-13.48	1.65	-15.13	-16.77		
NFκB	2.29	3.39	5.68	9.06		
Notch	-5.36	1.77	-3.59	-1.82		

FOXO-PI3K	6.08	3.62	9.70	13.32
JAK-STAT1/2	-5.56	2.57	-2.98	-0.41
JAK-STAT3	-6.08	3.40	-2.69	0.71
TGFβ	-15.90	2.49	-13.41	-10.92

Supplementary Table 2: Mean plus 1 and 2 SD of pathway activity scores in healthy children (n=93; GSE26440, GSE26378, GSE4607, GSE9692, GSE8121 and GSE13904) and adults (n=37; GSE57065 and GSE95233). *for HH mean minus SD.

T-test one sided	Su	rvivors day 1 vs da	ay 3	Non	survivors day 1 vs	day 3
		paired			paired	
			numbers day			numbers day
	p-value	significance	1 / day 3	p-value	significance	1 / day 3
MAPK-AP1	0.37	-	17/17	0.82	-	8/8
AR	0.19	-	17/17	0.06	-	8/8
ER	0.36	-	17/17	0.73	-	8/8
FOXO-PI3K	0.23	-	17/17	0.85	-	8/8
нн	0.67	-	17/17	0.79	-	8/8
ΝϜκΒ	0.57	-	17/17	0.92	-	8/8
Notch	0.57	-	17/17	0.67	-	8/8
JAK-STAT1/2	0.06	-	17/17	0.93	-	8/8
JAK-STAT3	0.58	-	17/17	0.73	-	8/8
TGFβ	0.40	-	17/17	0.61	-	8/8

T-test one sided	Survivors day 1 vs day 3			Non su	ırvivors day 1 vs	day 3
		unpaired			unpaired	
	p-value	significance	numbers day 1 / day 3	p-value	significance	numbers day 1 / day 3
MAPK-AP1	0.12	-	31/19	0.74	-	15/9
AR	0.03	*	31/19	0.31	-	15/9
ER	0.24	-	31/19	0.41	-	15/9
FOXO-PI3K	0.11	-	31/19	0.79	-	15/9
нн	0.79	-	31/19	0.67	-	15/9
ΝϜκΒ	0.43	-	31/19	0.60	-	15/9
Notch	0.50	-	31/19	0.79	-	15/9
JAK-STAT1/2	0.09	-	31/19	0.62	-	15/9
JAK-STAT3	0.44	-	31/19	0.66	-	15/9
TGFβ	0.05	-	31/19	0.49	-	15/9

Supplementary Table 3: Paired and unpaired one sided t-test for survivors and non survivors day 1 vs

day 3 from dataset GSE95233. *p <0.05, **p < 0.01, - not significant.

	Mean							
			Child	dren			Adults	
Pathway	GSE4607	GSE26440	GSE8121	GSE9692	GSE13904	GSE26378	GSE57065	GSE95233
MAPK-AP1	-9.8	-10.1	-9.6	-9.3	-9.5	-9.1	-8.3	-7.5
AR	-15.3	-15.2	-15.3	-15.3	-15.7	-15.6	-13.1	-11.0
ER	-18.4	-18.6	-18.4	-18.0	-18.7	-17.0	-16.6	-13.3
нн	-13.6	-14.2	-13.4	-13.3	-13.6	-14.4	-13.4	-10.6
NFκB	0.8	1.0	1.0	2.0	1.0	3.4	6.0	0.8
Notch	-5.1	-5.9	-5.1	-5.0	-6.2	-5.9	-4.3	-5.7
FOXO-PI3K	4.9	4.9	4.6	5.1	5.1	6.1	10.2	5.0
JAK-STAT1/2	-5.7	-5.6	-5.5	-5.6	-5.8	-5.0	-5.4	-5.9
JAK-STAT3	-7.7	-7.5	-8.1	-8.2	-8.1	-8.3	-2.1	-0.6
TGFβ	-17.0	-17.4	-17.1	-16.6	-16.8	-16.8	-13.2	-12.6

		SD							
			Chi	ldren			Ad	ults	
Pathway	GSE4607	GSE26440	GSE8121	GSE9692	GSE13904	GSE26378	GSE57065	GSE95233	
MAPK-AP1	1.9	2.0	1.7	1.5	1.2	1.5	0.8	1.0	
AR	1.4	1.8	1.2	1.3	1.3	1.7	1.2	0.6	
ER	0.9	1.1	0.9	0.9	1.0	0.8	1.1	1.2	
нн	1.5	1.4	1.6	1.8	1.6	1.0	1.2	0.9	
ΝϜκΒ	3.2	3.1	3.3	3.3	2.5	1.8	1.9	3.5	
Notch	2.0	1.6	1.5	1.6	2.0	1.5	1.4	1.6	
FOXO-PI3K	1.1	2.6	1.2	1.3	1.3	2.4	2.2	1.9	
JAK-STAT1/2	1.9	2.3	1.8	2.0	2.1	1.5	3.8	0.7	
JAK-STAT3	1.6	1.6	1.4	1.0	1.3	2.3	1.5	1.2	
TGFβ	3.0	3.1	2.3	2.2	3.1	3.1	2.1	1.2	

Supplementary Table 4: Mean and standard deviation PAS of each dataset including healthy children and adults.

Sepsis diagnosed	sepsis confirmed	No sepsis	
Test positive	308	3	311
Test negative	91	90	181
	399	93	492

Dying from sepsis	sepsis nonsurvival	sepsis survival	
Test positive	42	157	199
Test negative	3	53	56
	45	210	255

Surviving sepsis	sepsis survival	sepsis non survival	
Test positive (below threshold)	53	3	56
Test negative (above threshold)	157	42	199
	210	45	255

Sensitivity	77%
Specificity	97%
Possitive prediction value (PPV)	99%
Negative prediction value (NPV)	50%
Fisher's Exact Test	p-value < 2.2e-16

Sensitivity	93%
Specificity	25%
Possitive prediction value (PPV)	21%
Negative prediction value (NPV)	95%
Fisher's Exact Test	p-value = 0.005023

Sensitivity	25%
Specificity	93%
Possitive prediction value (PPV)	95%
Negative prediction value (NPV)	21%
Fisher's Exact Test	p-value = 0.005023

Supplementary table 6: TGFβ sensitivity, specificity, PPV and NPV.

Sepsis diagnosed	sepsis confirmed	No sepsis	
Test positive	254	2	256
Test negative	145	91	236
	399	93	492

Sensitivity	64%
Specificity	98%
Possitive prediction value (PPV)	99%
Negative prediction value (NPV)	39%
Fisher's Exact Test	p-value < 2.2e-16

Dying from sepsis	sepsis nonsurvival	sepsis survival	
Test positive	31	142	173
Test negative	14	68	82
	45	210	255

Sensitivity	69%
Specificity	32%
Possitive prediction value (PPV)	18%
Negative prediction value (NPV)	83%

				Fisher's Exact Test	p-value = 1
Surviving sepsis	sepsis survival	sepsis non survival		Sensitivity	32%
Test positive (below threshold)	68	14	82	Specificity	69%
Test negative (above threshold)	142	31	173	Possitive prediction value (PPV)	83%
	210	45	255	Negative prediction value (NPV)	18%
				Fisher's Exact Test	p-value = 1

Supplementary table 5: AR pathway assay for sepsis diagnosis and prognosis: sensitivity, specificity, PPV and NPV.

References:

- J. L. Wynn *et al.*, "The influence of developmental age on the early transcriptomic response of children with septic shock," *Mol Med*, vol. 17, no. 11–12, pp. 1146–1156, 2011, doi: 10.2119/molmed.2011.00169.
- [2] H. R. Wong *et al.*, "Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome," *Physiol Genomics*, vol. 30, no. 2, pp. 146–155, Jul. 2007, doi: 10.1152/physiolgenomics.00024.2007.
- [3] H. R. Wong *et al.*, "Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum," *Crit Care Med*, vol. 37, no. 5, pp. 1558– 1566, May 2009, doi: 10.1097/CCM.0b013e31819fcc08.
- [4] T. P. Shanley *et al.*, "Genome-Level Longitudinal Expression of Signaling Pathways and Gene Networks in Pediatric Septic Shock," *Mol Med*, vol. 13, no. 9–10, pp. 495–508, 2007, doi: 10.2119/2007-00065.Shanley.
- [5] N. Cvijanovich *et al.*, "Validating the genomic signature of pediatric septic shock," *Physiol Genomics*, vol. 34, no. 1, pp. 127–134, Jun. 2008, doi: 10.1152/physiolgenomics.00025.2008.
- [6] M.-A. Cazalis et al., "Early and dynamic changes in gene expression in septic shock patients: a genome-wide approach," *Intensive Care Med Exp*, vol. 2, no. 1, p. 20, Dec. 2014, doi: 10.1186/s40635-014-0020-3.
- [7] F. Venet *et al.*, "Modulation of LILRB2 protein and mRNA expressions in septic shock patients and after ex vivo lipopolysaccharide stimulation," *Hum Immunol*, vol. 78, no. 5–6, pp. 441–450, Jun. 2017, doi: 10.1016/j.humimm.2017.03.010.
- [8] M. T. McClain *et al.*, "Dysregulated transcriptional responses to SARS-CoV-2 in the periphery," *Nature Communications*, vol. 12, no. 1, Art. no. 1, Feb. 2021, doi: 10.1038/s41467-021-21289-y.